naltrexone low dose delayed burst release (SP-104) / Sorrento - LARVOL DELTA

Pharmacokinetics of SP-104 (clinicaltrials.gov) - P1 | N=18 | Completed | Sponsor: Scilex Pharmaceuticals, Inc. | Recruiting ➔ Completed

Trial completion

Study to Evaluate the Pharmacokinetics of SP-104 (clinicaltrials.gov) - P1 | N=18 | Recruiting | Sponsor: Scilex Pharmaceuticals, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open

Study to Evaluate the Safety of SP-104 (clinicaltrials.gov) - P1 | N=52 | Completed | Sponsor: Scilex Pharmaceuticals, Inc. | Recruiting ➔ Completed

Trial completion

Study to Evaluate the Safety of SP-104 (clinicaltrials.gov) - P1; N=52; Recruiting; Sponsor: Scilex Pharmaceuticals, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open

Study to Evaluate the Pharmacokinetics of SP-104 (clinicaltrials.gov) - P1; N=18; Not yet recruiting; Sponsor: Scilex Pharmaceuticals, Inc.

New P1 trial